Grunze Heinz, Csehi Réka, Born Christoph, Barabássy Ágota
Psychiatrie Schwäbisch Hall, Schwäbisch Hall, Germany.
Paracelsus Medical University, Nuremberg, Germany.
Front Psychiatry. 2021 Dec 14;12:803208. doi: 10.3389/fpsyt.2021.803208. eCollection 2021.
The dopaminergic system plays a central and decisive role in substance use disorder (SUD), bipolar disorder (BD), and possibly in a subgroup of patients with refractory depression. Common genetic markers and underlying cellular processes, such as kindling, support the close link between these disorders, which is also expressed by the high rate of comorbidity. Although partial dopamine agonists/antagonists acting on D and D receptors have an established role in treating BD, their usefulness in SUD is less clear. However, dopamine D receptors were shown to play a central role in SUD and BD, making D/D partial agonists/antagonists a potential target for both disorders. This narrative review examines whether these substances bear the promise of a future therapeutic approach especially in patients with comorbid BD and SUD.
多巴胺能系统在物质使用障碍（SUD）、双相情感障碍（BD）以及可能在难治性抑郁症患者亚组中发挥着核心且决定性的作用。常见的遗传标记和潜在的细胞过程，如点燃效应，支持了这些疾病之间的紧密联系，这也通过高共病率表现出来。尽管作用于D和D受体的部分多巴胺激动剂/拮抗剂在治疗双相情感障碍方面已确立了作用，但其在物质使用障碍中的效用尚不清楚。然而，多巴胺D受体已被证明在物质使用障碍和双相情感障碍中起核心作用，使得D/D部分激动剂/拮抗剂成为这两种疾病的潜在靶点。本叙述性综述探讨了这些物质是否有望成为未来的治疗方法，尤其是对于双相情感障碍和物质使用障碍共病的患者。
